Spinal Fluid Protein Test Predicts Alzheimer's Progression 3 Years in Advance

One of the major problems with Alzheimer's is late diagnosis. By the time a patient is diagnosed, the damage is already advanced. A new study in Nature Communications presents a breakthrough: two proteins in spinal fluid that can predict who will transition from MCI to dementia.

The Proteins: NPTX1 and NPTXR

NPTX1 and NPTXR (Neuronal Pentraxin) are proteins whose role is to maintain synapses. When their levels drop in the cerebrospinal fluid (CSF), it is a sign that synapses are deteriorating, an early sign of Alzheimer's.

The Study

An international team recruited 635 participants in two separate cohorts, in China and Norway, across the full spectrum of the disease. They were measured for NPTX as well as established markers: pTau181 and Neurofilament Light Chain (NfL).

Key Findings

1. Correlation with disease stage: NPTX levels decrease with Alzheimer's progression
2. Correlation with MRI damage: Thinning of the cerebral cortex in Alzheimer's-vulnerable areas
3. Predicting progression: Low baseline levels predict transition to dementia within about two to three years
4. Complementing existing markers: NPTX often outperformed or complemented pTau181 and Neurofilament Light Chain (NfL)

Why Does This Matter?

New drugs like lecanemab cost around $26,500 per year (and total treatment cost, including monitoring and imaging, is even higher) and come with side effects. A marker that predicts who is likely to decline could in the future help target treatment.

What Does This Mean for You?

It is important to understand: NPTX is currently a promising research marker, not a clinically available or validated test for medical use. The researchers themselves emphasize that larger studies are needed before this can be translated into clinical practice. Currently, those with memory complaints or a family history of Alzheimer's can consult a neurologist about existing markers (such as pTau181 and Neurofilament).

The Bottom Line

Early research suggests that a single test may predict decline years in advance. If the finding is confirmed in further studies, it could open a window for early intervention, which is usually associated with better outcomes.